Ibrexafungerp shows promise against recurrent vulvovaginal candidiasis in phase 3 trial
There are currently no approved treatments for the prevention of recurrent VVC, but Scynexis said it will submit the new phase 3 data to the FDA in the first half of 2022 and expects that ibrexafungerp tablets will be approved for this indication by the end of the year.
Ibrexafungerp shows promise against recurrent vulvovaginal candidiasis in phase 3 trial Read More »